The cell and gene therapy industry is growing rapidly, and as a result, faces new challenges. Realizing the potential of innovative cell and gene therapy treatments relies upon the industry’s ability to meet these challenges.

HemaCare recognizes two major needs of advancing treatments: quality starting materials and refined manufacturing processes. This discussion will explore:

• how the quality of starting materials impacts all stages of production—from R&D through commercialization.
• why consistent process control is essential to accomplishing quality, simplified, large-scale manufacturing on a global scale.
• How HemaCare plans to address these needs and contribute to the future successes of cell and gene therapies.